Initial data looking at safety and efficacy of an interatrial septal occluder with a bioresorbable frame show promise for closing atrial septal defects (ASDs), but the study authors suggest a redesign ...

Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...

February 7, 2008 (Chicago, IL) - Doctors and regulators concerned about the spike in off-label patent foramen ovale (PFO) closure procedures now have some numbers to fall back on. A research letter ...

NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...

Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...

Thrissur General Hospital’s Cardiology department has marked a major milestone in cardiac care by successfully performing a rare heart procedure known as an ‘Atrial Septal Defect (ASD) Device Closure’ ...

Expert Rev Cardiovasc Ther. 2007;5(6):1135-1146. Diagnosing a secundum ASD is more often than not incidental because the defect normally causes symptoms late in adult life. Echocardiography and MRI ...

" The treatment of choice for ASDs is minimally invasive transcatheter closure, a procedure that provides patients with a safe and effective alternative to traditional surgical interventions." s aid ...